Drug Trial Radar · NCT06366451
PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC
Last checked: Nov 19, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
17
Actual
Start
May 22, 2024
Primary completion
Mar 25, 2026
Study completion Mar 25, 2026
Sponsor
- Lead sponsor
- Presage BiosciencesIndustry
- Sponsor type
- Industry
- Collaborators
- AstraZeneca
- First posted
- Apr 16, 2024
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, open-label, Phase 0 substudy designed to evaluate the localized pharmacodynamics (PD) of rilvegostomig, volrustomig, sabestomig, and AZD9592 within the tumor microenvironment (TME) when administered intratumorally in microdose quantities via the CIVO device in patients presenting with Head and Neck Squamous Cell Carcinoma (HNSCC) with a surface accessible lesion, who are scheduled for tumor and/or regional node dissection as part of their standard treatment. PD effects due to injected investigational agents, either as single agents or as AZD9592 drug combinations with the evaluated biologics, will be compared to those elicited by pembrolizumab alone, which will also be injected in microdose quantities via the CIVO device.
Conditions
- Head and Neck Squamous Cell Carcinoma
Interventions
RilvegostomigBiological
Intratumoral microdose injection by the CIVO device.
VolrustomigBiological
Intratumoral microdose injection by the CIVO device.
SabestomigBiological
Intratumoral microdose injection by the CIVO device.
AZD9592Biological
Intratumoral microdose injection by the CIVO device.
PembrolizumabBiological
Intratumoral microdose injection by the CIVO device.
AZD9592 + RilvegostomigCombination product
Intratumoral microdose injection by the CIVO device.
AZD9592 + VolrustomigCombination product
Intratumoral microdose injection by the CIVO device.
AZD9592 + SabestomigCombination product
Intratumoral microdose injection by the CIVO device.
AZD9592 + PembrolizumabCombination product
Intratumoral microdose injection by the CIVO device.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluation of signature scores using Gene Set Variability Analysis within regions injected with microdoses of rilvegostomig, volrustomig, sabestomig, AZD9592, or pembrolizumab as single agents or as AZD9592 drug combinations with the evaluated biologicsTime frame: 1 to 3 days after microdose injection
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
UC Davis
Sacramento, California
Montefiore Medical Center
The Bronx, New York
University of North Carolina
Chapel Hill, North Carolina
Oregon Health & Science University (OHSU)
Portland, Oregon
University of Pennsylvania
Philadelphia, Pennsylvania
Sarah Cannon Medical Center
Charleston, South Carolina
Medical University of South Carolina
Charleston, South Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.